LivaNova (NASDAQ:LIVN) Rating Lowered to Peer Perform at Wolfe Research

Wolfe Research cut shares of LivaNova (NASDAQ:LIVN) from an outperform rating to a peer perform rating in a research note published on Wednesday, Marketbeat Ratings reports.

Other equities research analysts also recently issued research reports about the company. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Robert W. Baird increased their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $64.20.

LivaNova Price Performance

LivaNova stock opened at $41.45 on Wednesday. The stock has a market capitalization of $2.25 billion, a P/E ratio of 98.69 and a beta of 1.00. LivaNova has a 12-month low of $40.37 and a 12-month high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm’s 50-day moving average is $47.65 and its two-hundred day moving average is $49.56.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On LivaNova

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue boosted its position in LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after acquiring an additional 425 shares during the period. abrdn plc lifted its stake in shares of LivaNova by 43.8% in the 3rd quarter. abrdn plc now owns 232,025 shares of the company’s stock worth $12,191,000 after acquiring an additional 70,618 shares during the period. Emerald Advisers LLC boosted its holdings in shares of LivaNova by 2.1% in the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock valued at $36,542,000 after acquiring an additional 14,302 shares in the last quarter. Atria Investments Inc increased its stake in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after acquiring an additional 331 shares during the period. Finally, State of New Jersey Common Pension Fund D lifted its position in LivaNova by 38.3% in the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.